Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...